Stocks · News reference

EXCLUSIVE: Imunon Says Phase 2 IMNN-001 Data Showed Lower MRD, Higher ctDNA Clearance And Favorable Safety In Frontline Ovarian Cancer; Preliminary Data Reinforces Immunotherapy’s Potential For Success In Currently Recruiting Phase 3 OVATION 3 Study

Jul 21, 2026, 12:30 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

SEC EDGARAug 11, 2026, 9:00 PMSEC EDGAR
8-K filing — Imunon, Inc. (IMNN)
Filed: 2026-08-11 AccNo: 0001493152-26-037170 Size: 204 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgar
IMNN
BenzingaAug 11, 2026, 12:02 PMBenzinga Newsdesk
Imunon Q2 EPS $(0.54) Beats $(0.93) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.93) by 41.94 percent. This is a 74.88 percent increase over losses of $(2.15) per share from the same
Read original at benzinga
IMNN
BenzingaAug 7, 2026, 9:05 PMBenzinga Insights
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
Read original at benzinga
ABCL AKAN BRTX HIND ICCM
BenzingaJul 30, 2026, 1:02 PMBenzinga Newsdesk
IMUNON Announces Its Phase 3 OVATION 3 Trial Of IMNN-001 In Patients With Ovarian Cancer Has Observed Rapid Site Activation And Above-Forecast Enrollment Rate
The trial advanced from protocol submission to site activation in approximately 6 months and from protocol approval to first patient randomized in approximately 2 months, a third of the time of the external industry
Read original at benzinga
IMNN